AR054258A1 - Composiciones farmaceuticas y metodos que comprenden una combinacion de un modulador selectivo de receptores estrogenicos y un inhibidor de aromatasa - Google Patents

Composiciones farmaceuticas y metodos que comprenden una combinacion de un modulador selectivo de receptores estrogenicos y un inhibidor de aromatasa

Info

Publication number
AR054258A1
AR054258A1 AR20060101616A ARP060101616A AR054258A1 AR 054258 A1 AR054258 A1 AR 054258A1 AR 20060101616 A AR20060101616 A AR 20060101616A AR P060101616 A ARP060101616 A AR P060101616A AR 054258 A1 AR054258 A1 AR 054258A1
Authority
AR
Argentina
Prior art keywords
phenyl
acceptable salt
aromatase inhibitor
prodrug
patient
Prior art date
Application number
AR20060101616A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR054258A1 publication Critical patent/AR054258A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AR20060101616A 2005-04-25 2006-04-24 Composiciones farmaceuticas y metodos que comprenden una combinacion de un modulador selectivo de receptores estrogenicos y un inhibidor de aromatasa AR054258A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67480705P 2005-04-25 2005-04-25

Publications (1)

Publication Number Publication Date
AR054258A1 true AR054258A1 (es) 2007-06-13

Family

ID=36693972

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20060101616A AR054258A1 (es) 2005-04-25 2006-04-24 Composiciones farmaceuticas y metodos que comprenden una combinacion de un modulador selectivo de receptores estrogenicos y un inhibidor de aromatasa

Country Status (6)

Country Link
EP (1) EP1937251A2 (ja)
JP (1) JP2006306872A (ja)
AR (1) AR054258A1 (ja)
CA (1) CA2605796A1 (ja)
TW (1) TW200716094A (ja)
WO (1) WO2006114702A2 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0711525A2 (pt) 2006-06-02 2011-11-01 Pear Tree Women S Health Care composição farmacêutica e método para tratar sintomas de vaginite atrófica
EP2070943A1 (en) * 2007-12-14 2009-06-17 Crystal Pharma, S.A. Process for obtaining 6-Alkylidenandrost-1,4-diene-3one
WO2011002096A1 (ja) * 2009-07-03 2011-01-06 独立行政法人理化学研究所 Ｐｅｔ用標識化合物
US9370505B2 (en) 2011-09-08 2016-06-21 Mereo Biopharma 2 Limited Pharmaceutical compositions comprising an aromatse inhibitors
WO2017189976A1 (en) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Targeted measure of transcriptional activity related to hormone receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US20040024044A1 (en) * 2000-09-08 2004-02-05 Di Salle Enrico Exemestane as chemopreventing agent
AR034142A1 (es) * 2000-09-08 2004-02-04 Sloan Kettering Inst Cancer Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
WO2003017974A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
CN1713915A (zh) * 2001-10-10 2005-12-28 法马西亚意大利公司 用甾族化合物预防和治疗骨丢失的方法
CN1929835A (zh) * 2004-01-13 2007-03-14 惠氏公司 芳香酶抑制剂治疗－相关的骨质疏松症的治疗
JP2008518902A (ja) * 2004-11-04 2008-06-05 ファイザー・プロダクツ・インク 乳癌のためのｃｔｌａ４抗体とアロマターゼ阻害剤の併用治療

Also Published As

Publication number Publication date
EP1937251A2 (en) 2008-07-02
CA2605796A1 (en) 2006-11-02
TW200716094A (en) 2007-05-01
JP2006306872A (ja) 2006-11-09
WO2006114702A2 (en) 2006-11-02
WO2006114702A3 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
JP5480623B2 (ja) Ｈｓｐ９０活性を調節するトリアゾール化合物
CY1109860T1 (el) Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις
AU2006272652B2 (en) 1,2,3-triazoles inhibitors of tubulin polymerization for the treatment of proliferative disorders
FR16C0021I2 (fr) Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives
AR054258A1 (es) Composiciones farmaceuticas y metodos que comprenden una combinacion de un modulador selectivo de receptores estrogenicos y un inhibidor de aromatasa
CA2983927A1 (en) K-ras modulators
JP2015500887A5 (ja)
GEP20115213B (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
CO5670328A2 (es) Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos
JP2016516043A5 (ja)
TNSN07111A1 (en) Preparation and use of biphenyl-4-yl- carbonylamino acid derivatives for the treatment of obesity.
MXPA04002037A (es) Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad.
MX2021006552A (es) Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita.
WO2003105771A3 (en) 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATES AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDINE-3-CARBOXYLATES FOR USE AS EDG RECEPTOR AGONISTS
MX2023001468A (es) Tratamiento de cancer de prostata.
RU2007102274A (ru) Пиперазиндионы как антагонисты рецептора окситоцина
JP2010503674A (ja) 血管形成治療用化合物
DE602006017728D1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
ATE403426T1 (de) Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen
BRPI0411324A (pt) composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes
RU2004104329A (ru) Ацилсемикарбазиды как ингибиторы циклинзависимой киназы, полезные в качестве противораковых и противопролиферативных агентов
RU2007147957A (ru) Комбинация производных пиримидиламинобензамида и иматиниба для лечения или профилактики пролиферативных заболеваний
EA201000656A1 (ru) Аминопроизводные 1,2,4-триазола в качестве модуляторов mglur5
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
RU2006108557A (ru) Фармацевтические композиции, включающие в себя сочетания производных 2-алкилиден-19-нор-витамина d и паратиреоидного гормона, и способы (лечения)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal